A Comparison of Adverse Reactions of the First Dose of Gam-COVID-vac (Sputnik V), Oxford/AstraZeneca COVID-19 Vaccine, Bharat Biotech (Covaxin), and (Sinopharm) BBIBP-CorV Vaccines

authors:

avatar HamidReza Samimagham ORCID 1 , avatar Mehdi Hassani Azad 2 , avatar Mohsen Arabi 3 , avatar Sobhan Montazer Ghaem 4 , avatar Kimiya Jafari 4 , avatar Dariush Hooshyar ORCID 4 , avatar Mitra Kazemi Jahromi ORCID 5 , *

Clinical Research Development Center, Shahid Mohammadi Hospital, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
Infectious and Tropical Diseases Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
Department of Family Medicine, Preventive Medicine and Public Health Research Center, Iran University of Medical Sciences, Tehran, Iran
Student Research Committee, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
Endocrinology and Metablism Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

how to cite: Samimagham H, Hassani Azad M, Arabi M, Montazer Ghaem S, Jafari K, et al. A Comparison of Adverse Reactions of the First Dose of Gam-COVID-vac (Sputnik V), Oxford/AstraZeneca COVID-19 Vaccine, Bharat Biotech (Covaxin), and (Sinopharm) BBIBP-CorV Vaccines. J Health Rep Technol. 2022;8(4):e122479. https://doi.org/10.5812/jhrt-122479.

References

  • 1.

    Carter-Timofte ME, Jørgensen SE, Freytag MR, Thomsen MM, Brinck Andersen N, Al-Mousawi A, et al. Deciphering the Role of Host Genetics in Susceptibility to Severe COVID-19. Front Immunol. 2020;11. https://doi.org/10.3389/fimmu.2020.01606.

  • 2.

    Mahmud R, Rahman MM, Alam I, Ahmed KGU, Kabir A, Sayeed S, et al. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial. J Int Med Res. 2021;49(5):3000605211013550. [PubMed ID: 33983065]. [PubMed Central ID: PMC8127799]. https://doi.org/10.1177/03000605211013550.

  • 3.

    Rahimi A, Samimagham HR, Azad MH, Hooshyar D, Arabi M, KazemiJahromi M. The efficacy of N-Acetylcysteine in severe COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial. Trials. 2021;22(1):271. [PubMed ID: 33845881]. [PubMed Central ID: PMC8040363]. https://doi.org/10.1186/s13063-021-05242-4.

  • 4.

    Samimagham HR, Hassani Azad M, Haddad M, Arabi M, Hooshyar D, KazemiJahromi M. The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):848. [PubMed ID: 33050945]. [PubMed Central ID: PMC7552598]. https://doi.org/10.1186/s13063-020-04773-6.

  • 5.

    Soleimanpour S, Yaghoubi A. COVID-19 vaccine: where are we now and where should we go? Expert Rev Vaccines. 2021;20(1):23-44. [PubMed ID: 33435774]. [PubMed Central ID: PMC7898300]. https://doi.org/10.1080/14760584.2021.1875824.

  • 6.

    Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39-51. [PubMed ID: 33069281]. [PubMed Central ID: PMC7561304]. https://doi.org/10.1016/S1473-3099(20)30831-8.

  • 7.

    Doroftei B, Ciobica A, Ilie OD, Maftei R, Ilea C. Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines. Diagnostics (Basel). 2021;11(4). [PubMed ID: 33804914]. [PubMed Central ID: PMC8063839]. https://doi.org/10.3390/diagnostics11040579.

  • 8.

    Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396(10249):479-88. [PubMed ID: 32702299]. [PubMed Central ID: PMC7836858]. https://doi.org/10.1016/S0140-6736(20)31605-6.